Monash University and ClinChoice have entered into a strategic partnership to accelerate the clinical development of innovative therapies.[1][2] The partnership combines Monash's research excellence and clinical ecosystem with ClinChoice's global development, regulatory and data science capabilities.[1][2] It mainly focuses on the early stages of clinical development so that new therapies can reach patients more quickly.[1][2] It was formally confirmed by a three-year Memorandum of Understanding (MoU) supporting collaboration in early- to late-stage clinical trials, including first-in-human studies and global multi-regional studies.[2] ClinChoice, a US-based global CRO, has over 30 years of experience, operates in 15 countries and has conducted over 3000 studies, mainly in oncology, immunology, inflammation, cardio-metabolic diseases and CNS.[1][2] The partnership strengthens collaboration between academia and industry through the Monash Technology Precinct and the Monash Boston Hub.[1][2] Citations speak of pride in joining forces for patient-centered research and innovation.[1][2]